Trexquant Investment LP Buys 87,249 Shares of Genmab A/S Sponsored ADR $GMAB

Key Points

• Trexquant Investment LP increased its stake in Genmab A/S by 23.0%, owning 467,185 shares valued at approximately $9.1 million as of the latest SEC filing.
• Several institutions have also expanded their holdings in Genmab, including Barclays PLC, which increased its ownership by 1,072.8% in the fourth quarter.
• Wall Street analysts have mixed ratings on Genmab, with an average rating of "Moderate Buy" and a price target set at $37.60, while Zacks Research downgraded their rating from "strong-buy" to "hold".

Trexquant Investment LP lifted its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 23.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467,185 shares of the company's stock after purchasing an additional 87,249 shares during the quarter. Trexquant Investment LP owned 0.07% of Genmab A/S worth $9,147,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in GMAB. Deep Track Capital LP bought a new position in shares of Genmab A/S during the fourth quarter worth approximately $41,740,000. Two Sigma Advisers LP lifted its stake in Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after purchasing an additional 938,455 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Genmab A/S in the fourth quarter valued at about $12,360,000. Finally, Russell Investments Group Ltd. boosted its stake in Genmab A/S by 111.5% in the first quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company's stock valued at $21,149,000 after buying an additional 569,345 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Price Performance

Shares of GMAB traded up $0.30 during trading hours on Thursday, hitting $27.38. 1,488,131 shares of the stock were exchanged, compared to its average volume of 1,375,520. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $27.91. The business has a 50-day moving average of $22.68 and a 200-day moving average of $21.42. The firm has a market capitalization of $17.57 billion, a P/E ratio of 13.76, a price-to-earnings-growth ratio of 7.86 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GMAB has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. HC Wainwright raised their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, August 15th. Truist Financial raised their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.